A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Refractory Generalized Myasthenia Gravis

Conditions: Myasthenia Gravis; Generalized Myasthenia Gravis Interventions: Biological: KYV-101; Drug: Standard lymphodepletion regimen Sponsors: Kyverna Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials